All In MedTech

Device Trial Radar · NCT03632954

Cytal® Wound Matrix and MicroMatrix® Wound Study

Use of Cytal® Wound Matrix and MicroMatrix® for the Management of Wounds

Last checked: Nov 20, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

37

Actual

Start

Dec 11, 2018

Primary completion

Jan 27, 2020

Study completion Jan 27, 2020

Sponsor

Lead sponsor
Integra LifeSciences CorporationPublic (IART)
Sponsor type
Industry
Collaborators
Winthrop University Hospital
First posted
Aug 16, 2018

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an observational study to assess the safety and efficacy of MicroMatrix® alone or in combination with Cytal® Wound Matrix on primary measures of wound healing.

Conditions

  • Wounds

Interventions

  • ACell ArmDevice

    Cytal® Wound Matrix and/or MicroMatrix®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Completely Healed WoundsTime frame: Up to 12 weeks
  2. Wound Size ChangeTime frame: Up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NYU Winthrop Hospital

    Long Island City, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.